Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q1 2018 · 10-Q
Revenue$11.57M$11.57M+218.5% vs Q1 2017 Net Income-$52.27M-$52.27MN/M vs Q1 2017 EPS Diluted-$0.81-$0.81N/M vs Q1 2017 Gross Profit$8,434,000+244.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Operating Cash Flow-$61,713,000N/M Free Cash Flowderived-$62,617,000N/M Margins · derivedGross margin72.9%+5.6 pt vs Q1 2017
Operating margin-449.5%+907.9 pt vs Q1 2017
Net margin-451.8%+933.9 pt vs Q1 2017
ended Mar 31, 2018 · filed May 10, 2018 · 40 d after period end